Scalable Public Health Empowerment, Research, and Education Sites (SPHERES)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorOxford University Clinical Research Unit Indonesia
About this trial
SPHERES is a health service research trial in the Indonesian primary care system designed to improve health system performance using a structured data-driven action model. The intervention empowers district health leaders to make data-informed decisions that will enhance outcomes across maternal, child, infectious, and non-communicable disease programs.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Residing in or participating in the district catchment areas
Receiving services from participating health care facilities
Health providers and district health officials consent to participate in data collection
Disqualifiers
Individuals (health workers or patients) who decline to provide informed consent.
Individuals who are not directly involved in or accessing services from health care facilities or district health offices.
Inability to provide consent due to cognitive impairment or acute illness for health workers or district health officials involved in data collection
Trial design
Design model
Sequential
Treatments tested in this trial
Prescription for Action (SPHERES Model)
Other interventionA system-level intervention consisting of: * a digital dashboard displaying local health services, outcome indicators, and operational data in a secure Public Health Data Theater; * structured monthly prescription guides targeting service improvements across three priority program areas; * monthly performance monitoring with district health leaders. The intervention is applied at the PHC level, all supported by digital capacity building, district-level deployment of implementation teams, and intersectoral secure health data exchange.
Treatment groups
1,750,000 Participants
are divided into 2 treatment groupsGroup A: SPHERES Intervention ArmExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Difference in neonatal mortality rate between intervention and control periods
Neonatal mortality per 1,000 live births, calculated using health facility and civil registration data, and community household sampling surveys
Time frame
Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)Secondary outcomes
1
Difference in complete antenatal care (ANC 6) visit coverage between intervention and control periods
Percentage of pregnant women completing ≥6 ANC visits calculated using health facility data, paper based registry, and/or community household sampling surveys
Time frame
Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)2
Difference in complete basic childhood immunization coverage between the intervention and control period
Proportion of children aged 12-23 months receiving all recommended basic childhood vaccines according to Indonesian Pediatric Society guidelines using health facility data, paper based registry, and/or community household sampling surveys
Time frame
Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)3
Difference in TB treatment success rate between intervention and control periods
Percentage of new bacteriologically confirmed TB patients with documented treatment success (cure or completion) calculated using health facility data
Time frame
Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)4
Difference in screening coverage for diabetes mellitus among adults between the intervention and control periods
Proportion of adults aged ≥40 screened for random blood glucose or fasting blood glucose calculated using health facility data
Time frame
Baseline up to 16 months, with data collected monthly at each site (i.e. baseline, at the end of month 1, at the end of month 2, and so on until at the end of month 16)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Oxford University Clinical Research Unit Indonesia
Lead sponsor
Summit Institute for Development, Indonesia
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: